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Diagnostic challenge of anti-GQ1b 
syndrome: diff erential diagnosis between 
Miller Fischer syndrome and Bickerstaff ’s 
brainstem encephalitis
Ivan Sonnenschein1, Zoran Tomić1, Olivio Perković1,2, Barbara Zadković1, Mira Bučuk1,2
ABSTRACT – Miller Fisher syndrome (MFS) may be considered as a rare variant of Guillain-Barré syn-
drome (GBS). Together with GBS, Bickerstaff ’s brainstem encephalitis and acute ophthalmoparesis without 
ataxia, MFS is in the group of anti-GQ1b syndrome disorders (anti-GQ1b Sy). Among all GBS variants, MFS 
is distinctive, presenting with acute symptoms of ophthalmoparesis, ataxia and arefl exia, but without pro-
gressive limb weakness as the most characteristic symptom of GBS. MFS is a clinical entity based on typical 
clinical presentation and defi ned symptoms, and the fi nding of specifi c anti-GQ1b antibodies is not suffi  cient 
for MFS diagnosis. Th e objective of this case report is to demonstrate the diversity of anti-GQ1b Sy clinical 
presentation. Here we describe a case of a male patient with acute bilateral ophthalmoparesis, mydriasis and 
unilateral right infranuclear facial nerve palsy, in whom muscle tendon refl exes were preserved and no atax-
ia was present. Serum antiganglioside antibody test was positive for anti-GQ1b antibody, confi rming the 
presupposed diagnosis of MFS. Although MFS is rare, it should be considered in patients with acute develop-
ment of ophthalmoplegia. In rare cases of MFS with uncommon presentation, as it was in our case, positive 
serum antiganglioside antibody test will lead to the right diagnosis.
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INTRODUCTION
Miller Fisher syndrome (MFS) is a rare acquired 
autoimmune polyneuropathy, a clinical variant of 
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Guillain-Barré syndrome (GBS) that was described 
in 1956 (1). It accounts for 5%-10% of all GBS cas-
es. Symptoms that make MFS diff erent from other 
GBS variants are acute ophthalmoplegia, ataxia 
and arefl exia, but without limb weakness. MFS is a 
clinical entity based on typical clinical presentation 
and defi ned symptoms and the fi nding of specifi c 
anti-GQ1b antibodies is not suffi  cient for MFS di-
agnosis. MFS is usually preceded by infection of 
gastrointestinal tract, manifesting in most cases 
with diarrhea. Even though not specifi c to MFS, 
anti-GQ1b antibodies are present in serum of more 
than 85% of patients with MFS (2,3). In 2001, Oda-
ka coined the term anti-GQ1b syndrome (anti-
GQ1b Sy) performing a large study on 194 patients 
(4) and proving the presence of anti-GQ1b anti-
body not only in MFS patients, but also in those 
GBS patients with ophthalmoplegia, Bickerstaff ’s 
brainstem encephalitis (BBE), acute ophthalmo-
paresis (AO) without ataxia, and those in whom 
the symptoms of MFS/GBS and BBE/GBS over-
lapped suggesting a common autoimmune mecha-
nism in the pathogenesis of these illnesses. In the 
clinical presentation they found that every patient 
in whom the symptoms of MFS and GBS (MFS/
GBS) and symptoms of BBE and GBS (BBE/GBS) 
overlapped had external ophthalmoplegia; every 
patient with MFS/GBS had hyporefl exia or arefl ex-
ia; every patient with MFS and BBE had ataxia; 
68% of the patients with MFS/GBS and 45% of 
those with BBE/GBS had ataxia; 91% of the pa-
tients with BBE/GBS, 67% with BBE, and 53% with 
AO had decreased or absent tendon refl exes. Th is 
work confi rmed, clinically and by immunological 
fi ndings, the close relation between MFS, GBS, 
BBE and AO. Th e course of MFS as well as that of 
BBE can be favorable, but it can be ameliorated 
with intravenous immunoglobulin (IVIG) treat-
ment or plasmapheresis (5,6). In one reported case 
of severe plasmapheresis and immunoglobulin 
therapy resistant BBE, treatment with rituximab 
was applied (7).
CASE REPORT
A 19-year-old male student was admitted to our 
department complaining of double and blurred vi-
sion that had occurred three days prior to admis-
sion. Moderate headache and unsteadiness while 
walking were present during the fi rst two days. 
Seven days before the onset of symptoms, he had 
diarrhea for one day, but otherwise his medical his-
tory was unremarkable. On neurological examina-
tion, ocular movements were impaired with prom-
inent limitation of abduction, moderate limitation 
of supraduction bilaterally, and his pupils were di-
lated with poor reaction to light. He had no limb 
weakness, no sensory impairment, and his gait was 
normal. He was alert, no ataxia was present, his 
tendon refl exes were normal and the plantar re-
sponse was fl exor at the onset and during the 
course of the disease. His physical examination 
and blood pressure were normal. Th ree days aft er 
admission, he developed right infranuclear facial 
palsy. He could not whistle or wrinkle his forehead 
on the right side and he could not close his right 
eye. Th ese fi ndings aft er admission, normal tendon 
refl exes and absence of ataxia made the diagnosis 
of MFS uncertain.
Th e results of blood tests including erythrocyte 
sedimentation rate, blood cell count, blood glu-
cose, liver and kidney enzyme analysis, thyroid en-
zyme analysis, as well as urine analysis revealed no 
abnormality. Testing for neurotropic viruses (her-
pes simplex, varicella-zoster, cytomegalovirus, Ep-
stein-Barr virus and human immunodefi ciency 
virus) as well as the results of Western blot analysis 
to exclude Lyme borreliosis were negative. Cere-
brospinal fl uid (CSF) analysis performed on day 7 
of symptom onset demonstrated albuminocyto-
logic dissociation with protein level up to 0.9 g/L. 
Th e analysis of antiganglioside antibody in serum 
was positive for anti-GQ1b antibody in the fi rst 
week. Nerve conduction studies of the facial nerves 
showed slowing of conduction velocities on the 
right side with normal compound action potential 
amplitude and absent blink refl ex on the right side 
and normal on the left  side. Peripheral motor and 
sensory nerve conduction studies in the upper and 
lower limbs (ulnar, median, peroneal, tibial and 
sural nerve bilaterally) were normal, as well as F-
wave studies (ulnar, peroneal and tibial nerve bilat-
erally). Magnetic resonance imaging of the brain 
was unremarkable.
According to history data, neurological examina-
tion, peripheral nerve conduction studies, results 
of CSF analysis, and additional result of positive 
antiganglioside anti-GQ1b antibodies, a variant of 
anti-GQ1b Sy was presupposed (probably BBE or 
MFS/BBE overlap) and IVIG therapy was started 
immediately. Th e patient gradually improved over 
the following month and achieved complete recov-
ery within two months.
DISCUSSION
Miller Fisher syndrome is well distinguished from 
classical GBS by its characteristic triad of symp-
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toms: ataxia, arefl exia and ophthalmoplegia. Some-
times it can be diffi  cult to diff erentiate MFS from 
BBE. BBE is considered to aff ect central nervous 
system, but decreased or absent tendon refl exes, 
ataxia, ophthalmoplegia as well as ptosis, mydriasis 
and facial palsy may be present in BBE and MFS. 
Albuminocytological dissociation in CSF may be 
present in both BBE and MFS (8). Anti-GQ1b an-
tibodies can be seen in both of these entities (8). 
Th ere are cases of BBE with atypical neurological 
symptoms (9). Because of the similarities in the 
clinical presentation of MFS and BBE, there is an 
opinion that they form a continuous spectrum 
with variable central and peripheral nervous sys-
tem involvement (10). Altered sensorium in BBE, 
if present, can make a distinction between these 
two entities. Among patients with MFS, some dif-
ferences in clinical presentation can be seen. Bae et 
al. report on a case of a woman with internal oph-
thalmoplegia as the fi rst symptom of MFS (11). 
Fleury et al. describe fi ve MFS patients with bilat-
eral acute mydriasis with or without external oph-
thalmoplegia (12). Sometimes it can be diffi  cult to 
presuppose the diagnosis of MFS when ophthal-
moplegia is the sole symptom, but if ataxia and are-
fl exia are present from the onset, or when they sub-
sequently develop, reaching the diagnosis is much 
easier. In both circumstances, the nerve conduc-
tion studies and the results of CSF analysis can be 
very helpful, but a positive result of antiganglioside 
anti-GQ1b antibody test is usually needed to con-
fi rm the diagnosis. In a series of 100 patients with 
isolated bilateral or unilateral abducens nerve pal-
sy, the diagnosis of atypical mild form of MFS was 
confi rmed in 25 patients who were anti-GQ1b an-
tibody positive (13). Our patient developed unilat-
eral infranuclear facial nerve palsy that is not quite 
common presentation of MFS, and to our knowl-
edge, it is mainly bilateral. Doo-Hyuk et al. de-
scribe four patients with MFS who developed fa-
cial palsy from day 8 to day 16 aft er initial symp-
tom onset and from day 5 to day 9 aft er IVIG 
treatment (14).
In our case, the signs of unilateral infranuclear 
right facial palsy developed six days aft er the initial 
symptoms of external and internal ophthalmople-
gia occurred, and before the treatment with IVIG. 
On neurological examination and during the dis-
ease course, neither ataxia nor arefl exia were 
present. Cases of MFS without ataxia have been 
previously reported, but they are rare (15). Clinical 
features, the results of blink refl ex analysis and the 
albuminocytologic dissociation in CSF led us to 
presume the presence of atypical MFS, which was 
confi rmed by the positive fi ndings of serum anti-
ganglioside anti-GQ1b antibodies.
CONCLUSION
Both BBE and MFS are considered to form the 
same and continuous clinical spectrum of the anti-
GQ1b Sy, as there is good evidence that both disor-
ders have similar clinical and laboratory features. 
We present our case in order to emphasize the di-
versity of anti-GQ1b Sy clinical presentation and 
to stress the importance of antiganglioside anti-
body testing in all, but even more in atypical forms, 
where this testing is important to confi rm the diag-
nosis.
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Dijagnostički izazov sindroma anti-GQ1b: 
diferencijalna dijagnoza između Miller-Fischerova 
sindroma i Bickerstaff ova encefalitisa moždanog 
debla
SAŽETAK – Miller Fisherov sindrom (MFS) može se smatrati rijetkom varijantom Guillain-Barréova 
 sindroma (GBS). MFS, zajedno s GBS, Bickerstaff ovim encefalitisom moždanog debla (BBE) i akutnom 
 oft almoparezom (AO) bez ataksije, pripada skupini poremećaja unutar anti-GQ1b sindroma (anti-GQ1b 
Sy). Između svih varijanta GBS, MFS se manifestira na specifi čan način akutnim razvojem oft almoplegije, 
ataksije i arefl eksije, no bez progresivne slabosti mišića ekstremiteta kao karakterističnog znaka GBS. MFS je 
klinički entitet temeljen na tipičnoj kliničkoj slici i određenim simptomima, no nalaz specifi čnih anti-GQ1b 
protutijela nije dovoljan za dijagnozu MFS. Cilj je ovoga članka prikazati različitosti kliničke prezentacije 
anti-GQ1b sindroma. Opisujemo slučaj bolesnika s naglim razvojem obostrane oft almoplegije, midrijaze i 
unilateralne desnostrane infranuklearne pareze ličnog živca, bez ataksije te urednih miotatskih refl eksa. S 
obzirom na kliničku sliku i razvoj simptoma postavljena je sumnja na MFS, što je potvrđeno i pozitivnim 
nalazom serumskih anti-GQ1b protutijela. U zaključku, premda se rijetko pojavljuje, na MFS treba pomi sliti 
u diferencijalnoj dijagnozi kod bolesnika s naglim razvojem oft almoplegije. U rijetkim slučajevima neuo-
bičajene prezentacije MFS-a, kao u našem slučaju, pozitivan nalaz antigangliozidnih protutijela omogućava 
postavljanje točne dijagnoze.
Ključne riječi:  antigangliozidna protutijela, anti-GQ1b sindrom, Bickerstaff ov encefalitis, Guillain-Barréov 
sindrom, Miller Fisherov sindrom
